Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …

Context Aims of bladder preservation in muscle-invasive bladder cancer (MIBC) are to offer
a quality-of-life advantage and avoid potential morbidity or mortality of radical cystectomy …

Background Tri-modality therapy (TMT) is a recognized treatment strategy for selected
patients with muscle-invasive bladder cancer (MIBC). Objective Report long-term outcomes …

Purpose Multiple prospective Radiation Therapy Oncology Group (RTOG) protocols have
evaluated bladder-preserving combined-modality therapy (CMT) for muscle-invasive …

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide
recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …

BACKGROUND: Whether organ-conserving treatment by combined-modality therapy (CMT)
achieves comparable long-term survival to radical cystectomy (RC) for muscle-invasive …

Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma
that originates from the urinary bladder is the most common subtype. These NCCN Clinical …

An in-depth overview of the normal-tissue radiation tolerance of the urinary bladder is
presented. The most informative studies consider whole-organ irradiation. The data on …

Purpose Phase II clinical studies suggest that hypoxic modification with carbogen and
nicotinamide (CON) may increase the efficacy of radiotherapy (RT). Patients and Methods …